Targeting CD19 in B-cell lymphoma: emerging role of SAR3419

References

• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) [webpage on the Internet]Bethesda, MDNational Cancer Institute2011 [updated Apr 2012]. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/Assessed July 10, 2013
   Google Scholar
• SwerdlowSHCampoEHarrisNLWHO Classification of Tumors of Hematopoietic and Lymphoid Tissues4th edLyon, FranceIARC2008
   Google Scholar
• HallekMChesonBDCatovskyDGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesBlood2008111125446545618216293
   PubMed Web of Science ®Google Scholar
• OwenRGTreonSPAl-KatibAClinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’sMacroglobulinemiaSemin Oncol200330211011512720118
   PubMed Web of Science ®Google Scholar
• The International Myeloma Working GroupCriteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working GroupBr J Haematol2003121574975712780789
   PubMed Web of Science ®Google Scholar
• GanemGCartronGGirinskyTHaasRLCossetJMSolal-CelignyPLocalized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooksInt J Radiat Oncol Biol Phys201078497598220970029
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [homepage on the Internet]NCCN Clinical Practice Guidelines in Oncology: NCCN Non-Hodgkin’s lymphoma Guidelines Version 1.2013 Available from: http://www.nccn.org/professionals/physician%20gls/f%20guidelines.aspAccessed July 10, 2013
   Google Scholar
• HiddemannWKnebaMDreylingMFrontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2005106123725373216123223
   PubMed Web of Science ®Google Scholar
• PerskyDOUngerJMSpierCMPhase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014J Clin Oncol200826142258226318413640
   PubMed Web of Science ®Google Scholar
• HabermannTMWellerEAMorrisonVARituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphomaJ Clin Oncol200624193121312716754935
   PubMed Web of Science ®Google Scholar
• HagbergHGisselbrechtCCORAL study groupRandomized phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomization to maintenance treatment with rituximab or not: an update of the CORAL studyAnn Oncol200617Suppl 4iv31iv3216702182
   PubMed Web of Science ®Google Scholar
• StiffPJUngerJMCookJRandomized phase III US/Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-int) or high IPI grade diffuse aggressive non-Hodgkin lymphomaJ Clin Oncol201129Suppl abstracta8001
   Google Scholar
• VitoloUChiappellaABrusamolinoEA randomized multicentre phase III study for first line treatment of young patients with high-risk (aaIPI 2-3) diffuse large B-cell lymphoma (DLBCL): Rituximab ®plus dose-dense chemotherapy CHOP14/megaCHOP14 with or without intensified high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Results of DLCL04 trial of Italian Lymphoma Foundation (FIL)Annals of Oncology201122Suppl 4a072iv106
   Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors ProjectN Engl J Med1993329149879948141877
   PubMed Web of Science ®Google Scholar
• Solal-CélignyPRoyPColombatPFollicular lymphoma international prognostic indexBlood200410451258126515126323
   PubMed Web of Science ®Google Scholar
• HosterEDreylingMKlapperWA new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood2008111255856517962512
   PubMed Web of Science ®Google Scholar
• CarterPImproving the efficacy of antibody-based cancer therapiesNat Rev Cancer20011211812911905803
   PubMed Web of Science ®Google Scholar
• GlennieMJvan de WinkelJGRenaissance of cancer therapeutic antibodiesDrug Discov Today200381150351012818520
   PubMed Web of Science ®Google Scholar
• TrailPABianchiABMonoclonal antibody drug conjugates in the treatment of cancerCurr Opin Immunol199911558458810508711
   PubMed Web of Science ®Google Scholar
• WuAMSenterPDArming antibodies: prospects and challenges for immunoconjugatesNat Biotechnol20052391137114616151407
   PubMed Web of Science ®Google Scholar
• TeicherBAChariRVAntibody conjugate therapeutics: challenges and potentialClin Cancer Res201117206389639722003066
   PubMed Web of Science ®Google Scholar
• AlleySCOkeleyNMSenterPDAntibody-drug conjugates: targeted drug delivery for cancerCurr Opin Chem Biol201014452953720643572
   PubMed Web of Science ®Google Scholar
• ReffMECarnerKChambersKSDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood19948324354457506951
   PubMed Web of Science ®Google Scholar
• DillmanROMagic bullets at last! Finally – approval of a monoclonal antibody for the treatment of cancer!!!Cancer Biother Radiopharm199712422322510851468
   PubMed Web of Science ®Google Scholar
• CoifferBLepageEBriereJCHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaN Engl J Med2002346423524211807147
   PubMed Web of Science ®Google Scholar
• GhielminiMSchmitzSFCogliattiSBProlonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 scheduleBlood2004103124416442314976046
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKBelchACVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood200510541417142315494430
   PubMed Web of Science ®Google Scholar
• ByrdJCPetersonBLMorrisonVARandomized phase 2 study of fudarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood2003101161412393429
   PubMed Web of Science ®Google Scholar
• KeatingMJFlinnIJainVTherapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood200299103554356111986207
   PubMed Web of Science ®Google Scholar
• ZinzaniPLTaniMPulsoniAA phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphomaAnn Oncol201223241542021536660
   PubMed Web of Science ®Google Scholar
• ZinzaniPLRossiGFranceschettiSPhase II trial of short course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patientsClin Cancer Res201016153998400420542986
   PubMed Web of Science ®Google Scholar
• KaminskiMSTuckMEstesJ131I-tositumomab therapy as initial treatment for follicular lymphomaN Engl J Med20053525
   Web of Science ®Google Scholar
• KaminskiMSTuckMEstesJTositumomab and iodine I-131 tositumomab for previously untreated, advanced stage, follicular lymphoma: median 10 year follow-up resultsBlood (ASH Annual Meeting Abstracts)2009114223759
   Web of Science ®Google Scholar
• YounesABartlettNLLeonardJPBrentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasN Engl J Med2010363191812182121047225
   PubMed Web of Science ®Google Scholar
• TedderTFCD19: a promising B cell target for rheumatoid arthritisNat Rev Rheumatol200951057257719798033
   PubMed Web of Science ®Google Scholar
• HaasKMTedderTFRole of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunityAdv Exp Med Biol200556012513915934172
   PubMed Web of Science ®Google Scholar
• BradburyLEKansasGSLevySEvansRLTedderTFThe CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 moleculesJ Immunol19921499284128501383329
   PubMed Web of Science ®Google Scholar
• PoeJCMinard-ColinVKountikovEIHaasKMTedderTFA c-Myc and Surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in miceJ Immunol201218952318232522826319
   PubMed Web of Science ®Google Scholar
• van ZelmMCReisliIvan der BurgMAn antibody-deficiency syndrome due to mutations in the CD19 geneN Engl J Med2006354181901191216672701
   PubMed Web of Science ®Google Scholar
• NadlerLMAndersonKCMartiGB4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytesJ Immunol198313112442506408173
   PubMed Web of Science ®Google Scholar
• ScheuermannRHRacilaECD19 antigen in leukemia and lymphoma diagnosis and immunotherapyLeuk Lymphoma1995185–63853978528044
   PubMed Web of Science ®Google Scholar
• AndersonKCBatesMPSlaughenhouptBLPinkusGSSchlossmanSFNadlerLMExpression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiationBlood1984636142414336609729
   PubMed Web of Science ®Google Scholar
• CarterRHMyersRGerminal center structure and function: lessons from CD19Semin Immunol2008201434818243730
   PubMed Web of Science ®Google Scholar
• LutzRJZuany-AmorimCVrignaudPMayoMFGuerifSXieHPreclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B-cell lymphomaProc Am Assoc Cancer Res2006473731
   Google Scholar
• GerberHPKung-SutherlandMStoneIPotent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomasBlood2009113184352436119147785
   PubMed Web of Science ®Google Scholar
• MohammadRMMohamedANSmithMRJawadiNSAl-KatibAA unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11)Cancer Genet Cytogenet199370162678221615
   PubMedGoogle Scholar
• MohamedANAl-KatibAEstablishment and characterization of a human lymphoma cell line (WSU-NHL) with 14; 18 translocationLeuk Res198812108338433143865
   PubMed Web of Science ®Google Scholar
• MohammadRMMohamedANKuKurugaMSmithMRAl-KatibAA human B-cell lymphoma line with de novo multidrug resistance phenotypeCancer1992696146814741540884
   PubMed Web of Science ®Google Scholar
• Al-KatibAMohammadRMMohamedANWSU-BL: a new Burkitt’s lymphoma cell line with capacity to differentiate in vitroAnn NY Acad Sci1989567317319
   Web of Science ®Google Scholar
• MohamedANMohammadRMKoopBFAl-KatibAEstablishment and characterization of a new human Burkitt’s lymphoma cell line (WSU-BL)Cancer1989645104110482527086
   PubMed Web of Science ®Google Scholar
• WeinsteinIBJoeAOncogene addictionCancer Res20086893077308018451130
   PubMed Web of Science ®Google Scholar
• TaubRKirschIMortonCTranslocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cellsProc Natl Acad Sci U S A19827924783778416818551
   PubMed Web of Science ®Google Scholar
• Dalla-FaveraRBregniMEriksonJPattersonDGalloRCCroceCMHuman c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cellsProc Natl Acad Sci U S A19827924782478276961453
   PubMed Web of Science ®Google Scholar
• BusslingerMTranscriptional control of early B cell developmentAnnu Rev Immunol200422557915032574
   PubMed Web of Science ®Google Scholar
• MonroeJGITAM-mediated tonic signaling through pre-BCR and BCR complexesNat Rev Immunol20066428329416557260
   PubMed Web of Science ®Google Scholar
• ChungEYPsathasJNYuDLiYWeissMJThomas-TikhonenkoACD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesisJ Clin Invest201212262257226622546857
   PubMed Web of Science ®Google Scholar
• PillayVGanHKScottAMAntibodies in oncologyN Biotechnol201128551852921473941
   PubMed Web of Science ®Google Scholar
• PillayVAllafLWildingALThe plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinasesNeoplasia200911544845819412429
   PubMed Web of Science ®Google Scholar
• YounesABeyond chemotherapy: new agents for targeted treatment of lymphomaNat Rev Clin Oncol201182859621151205
   PubMed Web of Science ®Google Scholar
  Erratum in:Nat Rev Clin Oncol20118312421480559
   PubMed Web of Science ®Google Scholar
• KupchanSMKomodaYCourtWAMaytansine, a novel anti-leukemic ansa macrolide from Maytenus ovatusJ Am Chem Soc1972944135413565062169
   PubMed Web of Science ®Google Scholar
• RemillardSRebhunLIHowieGAKupchanSMAntimitotic activity of the potent tumor inhibitor maytansineScience19751894207100210051241159
   PubMed Web of Science ®Google Scholar
• BlancVBousseauACaronACarrezCLutzRJLambertJMSAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignanciesClin Cancer Res201117206448645822003072
   PubMed Web of Science ®Google Scholar
• ChabnerBALevineASJohnsonBLYoungRCInitial clinical trials of maytansine, an antitumor plant alkaloidCancer Treat Rep1978623429433348311
   PubMedGoogle Scholar
• BlumRHKahlertTMaytansine: a phase I study of an ansa macrolide with antitumor activityCancer Treat Rep1978623435438348312
   PubMedGoogle Scholar
• CabanillasFRodriguezVHallSWBurgessMABodeyGPFreireichEJPhase I study of maytansine using a 3-day scheduleCancer Treat Rep1978623425428348310
   PubMedGoogle Scholar
• EaganRTIngleJNRubinJFrytakSMoertelCGEarly clinical study of an intermittent schedule for maytansine (NSC-153858): brief communicationJ Natl Cancer Inst19786019396628025
   PubMedGoogle Scholar
• IssellBFCrookeSTMaytansineCancer Treat Rev197854199207367597
   PubMed Web of Science ®Google Scholar
• EricksonHKParkPUWiddisonWCAntibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processingCancer Res20066684426443316618769
   PubMed Web of Science ®Google Scholar
• KovtunYVAudetteCAYeYAntibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigenCancer Res20066663214322116540673
   PubMed Web of Science ®Google Scholar
• Al-KatibAMAboukameelAMohammadRBisseryMCZuany-AmorimCSuperior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin’s lymphomaClin Cancer Res200915124038404519509168
   PubMed Web of Science ®Google Scholar
• DiJosephJFGoadMEDougherMMPotent and specific antitumor efficacy of CMC-544, aCD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphomaClin Cancer Res200410248620862915623646
   PubMed Web of Science ®Google Scholar
• YounesAKimSRomagueraJPhase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphomaJ Clin Oncol201230222776278222753910
   PubMed Web of Science ®Google Scholar
• CoifferBRibragVDupuisJPhase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL)J Clin Oncol201129suppl abstract8017
   Google Scholar
• CarolHSzymanskaBEvansKThe anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemiaClin Cancer Res20131971795180523426279
   PubMed Web of Science ®Google Scholar